Though significant strides in the prevention and therapy of GVHD have been made over the last two decades, a greater understanding of the molecular immunology of this complication is still needed in order to develop more effective therapies to eliminate GVH while maintaining beneficial alloreactivity against malignancy. Though there may not be a single therapeutic approach that will achieve this aim, the considerable experimental and clinical evidence indicates that modulation of

0 0

Post a comment